Immunology in diabetes: An update

Diabetes/Metabolism Reviews

Volumn 14, Issue 1, 1998, Pages 3-29

  Schranz, Dorota B ^a   Lernmark, Åke ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Autoantibodies; Autoantigens; HLA; Prediction; Type 1 diabetes, autoimmunity

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; AUTOANTIBODY; AUTOANTIGEN; CARBOXYPEPTIDASE H; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTAMATE DECARBOXYLASE; GLYCOLIPID; HEAT SHOCK PROTEIN; IA ANTIBODY; INSULIN; INSULIN ANTIBODY; NICOTINAMIDE; PANCREAS ISLET CELL ANTIBODY; T LYMPHOCYTE ANTIGEN;

ARTICLE; CLINICAL TRIAL; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0031958594     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199803)14:1<3::AID-DMR206>3.0.CO;2-T     Document Type: Article

References (248)

1. Nepom GT: Immunogenetics and IDDM. Diabetes Rev 1: 93-103, 1993.
2. Sanjeevi CB, Kockum I, and Lernmark A: The role of major histocompatibility complex in insulin-dependent diabetes mellitus. Curr Sci 2: 3-11, 1995.
3. DERIG: Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes Epidemiology Research International Group. Diabetes 37: 1113-1119, 1988.
4. Tuomilehto J, Rewers M, Reunanen A, Lounamaa P, Lounamaa R, Tuomilehto-Wolf E. and Åkerblom HK: Increasing trend in type 1 (insulin-dependent) diabetes mellitus in childhood in Finland. Diabetologia 34: 282-287, 1991.
5. Dahlquist G, Blom L, Tuvemo T, Nyström L, Sandström A, and Wall S: The Swedish Childhood Diabetes Study: results from a nine year case register and one year case-referent study indicating that type 1 (insulin-dependent) diabetes mellitus is associated with both type 2 (non-insulin-dependent) diabetes mellitus and autoimmune disorders. Diabetologia 32: 2-6, 1989.
6. Muntoni S, Songini M, and IDDM SCGfEo: High incidence rate of IDDM in Sardinia. Diabetes Care 15: 1317-1322, 1992.
7. Green A, Gale EA, and Patterson CC: Incidence of childhood-onset insulin-dependent diabetes mellitus: the EURODIAB ACE Study. Lancet 339: 905-909, 1992.
8. Hanafusa T, Miyazaki A, and Miyagawa J: Examination of islets in the pancreas biopsy specimens from newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 33: 105-111, 1990.
9. Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, and Harrison LC: High level of concordance between assays for glutamic acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes 43: 1005-1009, 1994.
10. Schmidli RS, Colman PG, and Bonifacio E: Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International Glutamic Acid Decarboxylase Workshop. Diabetes 44: 636-640, 1995.
11. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, and Paguette TL: Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222: 1337-1339, 1983.
12. Greenbaum CJ, Palmer JP, Kuglin B, and Kolb H: Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody measurement. J Clin Endocrinol Metab 74: 1040-1044, 1992.
13. Lernmark Å, and Baekkeskov S: Islet cell antibodies: theoretical and practical implications. Diabetologia 212: 431-435, 1981.
14. Baekkeskov S, Nielsen JH, Marner B, Bilde T, Ludvigsson J, and Lernmark Å: Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 298: 167-169, 1982.
15. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, and De Camilli P: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347: 151-156, 1990.
16. Karlsen AE, Hagopian WA, Grubin CE, Dube S, Disteche CM, Adler DA, Bärmeier H, Mathewes S, Grant FJ, Foster D, and Lernmark Å: Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci USA 88: 8337-8341, 1991.
17. Grubin C, Daniels T, Karlsen AE, Boel E, Hagopian WA, and Lernmark Å: The cDNA-directed, in vitro-synthesized nascent peptide of glutamic acid decarboxylase (GAD2) is the autoantigen in insulin-dependent diabetes. Clin Res 40: 299A, 1992.
18. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, Karlsen AE, Boel E, Michelsen B, and Lernmark Å: A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37: 344-350, 1994.
19. Petersen JS, Hejnaes KR, Moody A, Karlsen AE, Marshall MO, Hoier-Madsen M, Boel E, Michelsen BK, and Dyrberg T: Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 43: 459-465, 1994.
20. Christie MR, Tun RYM, Lo SSS, Cassidy D, Brown TJ, Hollands J, Shattock M, Bottazzo GF, and Leslie RDG: Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Diabetes 41: 782-787, 1992.
21. Rabin DU, Pleasic SM, Shapiro JA, Yoo-Warren H, Oles J, Hicks JM, Goldstein DE, and Rae PM: Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152: 3183-3187, 1994.
22. Payton MA, Hawkes CJ, and Christie MR: Relationship of the 37,000- and 40,000-Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J Clin Invest 96: 1506-1511, 1995.
23. Lan MS, Lu J, Goto Y, and Notkins AL: Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 13: 505-514, 1994.
24. Lu J, Notkins AL, and Lan MS: Isolation, sequence and expression of a novel mouse brain cDNA, mIA-2, and its relatedness to members of the protein tyrosine phosphatase family. Biochem Biophys Res Commun 204: 930-936, 1994.
25. Cui L, Yu W-P, DeAizpurua HJ, Schmidli RS, and Pallen CJ: Cloning and characterization of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes. J Biol Chem 271: 24817-24813, 1996.
26. Wasmeier C, and Hutton JC: Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem 271: 18161-18170, 1996.
27. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, and Eisenbarth GS: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926-933, 1996.
28. Wiest-Ladenburger U, Hartmann R, Hartmann U, Berling K, Böhm BO, and Richter W: Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 46: 565-571, 1997.
29. Bach J-F: Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15: 516-542, 1994.
30. Atkinson MA, and Maclaren NK: The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1428-1436, 1994.
31. Maclaren NK, and Alkinson MA: Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Mol Med Today 3: 76-83, 1997.
32. Palmer JP, and Lernmark Å: Pathophysiology of type 1 (insulin-dependent) diabetes. In Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice, Vol. 5 (5th edn) by Daniel Porte J, and Sherwin RS, Elsevier, Stamford, CT, 1996, pp. 455-486.
33. Dahlquist G, and Kallén B: Maternal-child blood group incompatibility and other perinatal events increase the risk for early-onset type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35: 671-675, 1990.
34. Dahlquist G, Blom L, and Lönnberg G: The Swedish Childhood Diabetes Study: a multivariate analysis of risk determinants for diabetes in different age groups. Diabetologia 34: 757-762, 1991.
35. Blom L, Nyström L, and Dahlquist G: The Swedish childhood diabetes study: vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 34: 176-181, 1991.
36. Helmke K, Otten A, Willems WR, Brockhaus R, Mueller-Eckhardt G, Stief T, Bertrams J, Wolf H, and Federlin K: Islet cell antibodies and the development of diabetes mellitus in relation to mumps infection and mumps vaccination. Diabetologia 29: 30-33, 1986.
37. Yoon J-W, Austin M, Onodera T, and Notkins AL: Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300: 1174-1179, 1975.
38. Yoon JW: Role of viruses in the pathogenesis of IDDM. Ann Med 23: 437-445, 1991.
39. Menser MA, Forrest JM, Honeyman MC, and Burgess JA: Diabetes, HLA-antigens and congenital rubella. Lancet ii: 1508-1509, 1974.
40. Ginsberg-Fellner F, Witt ME, Yagihashi S, Dobersen MJ, Taub F, Fedun B, McEvoy RC, Roman SH, Davies TF, Cooper LZ, Rubinstein P, and Notkins AL: Congenital rubella syndrome as a model for type 1 (insulin-dependent) diabetes mellitus: increased prevalence of islet cell surface antibodies. Diabetologia 27: 87-89, 1984.
41. Gianani R, and Sarvetnick N: Viruses, cytokines, antigens, and autoimmunity. Proc Natl Acad Sci USA 93: 2257-2259, 1996.
42. Clements GB, Galbraith DN, and Taylor KW: Coxsackie B virus infection and onset of childhood diabetes. Lancet 346: 221-223, 1995.
43. Banatvala JE, Schernthaner G, Schober E, De Silva LM, Bryant J, Borkenstein M, Brown D, and Menser MA: Coxsackie B, mumps, rubella and cytomegalovirus specific IgM response in patients with juvenile-onset diabetes mellitus in Britain, Austria and Australia. Lancet ii: 1409-1412, 1985.
44. Tuvemo T, Dahlquist G, FRisk G, Blom L, Friman G, Landin-Olsson M, and Diderholm H: The Swedish childhood diabetes study III: IgM against coxsackie B viruses in newly diagnosed type 1 (insulin-dependent) diabetic children: no evidence of increased antibody frequency. Diabetologia 32: 745-747, 1989.
45. Karjalainen J, Knip M, Hyöty P, Leinikki P, Ilonen J, Käär M-L, and Åkerblom HK: Relationship between serum insulin autoantibodies, islet cell antibodies and Coxsackie-B4 and mumps virus-specific antibodies at the clinical manifestation of type 1 (insulin-dependent) diabetes. Diabetologia 31: 146-152, 1988.
46. Dippe SE, Miller M, Bennett PH, Maynard JE, and Berquist KR: Lack of causal association between coxsackie B4 virus infection and diabetes. Lancet i: 1314-1317, 1975.
47. Kaufman DJ, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, and Tobin AJ: Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 89: 283-292, 1992.
48. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, and Maclaren NK: Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 94: 2125-2129, 1994.
49. Endl J, Otto H, Jung G, Dreisbusch B, Donie F, Stahl P, Elbracht R, Schmitz G, Meinl E, Hummel M, Ziegler AG, Wank R, and Schendel DJ: Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 99: 2405-2415, 1997.
50. Wicker LS, Chen SL, Nepom GT, Elliott JF, Freed DC, Bansal A, Zheng S, Herman A, Lernmark A, Zaller DM, Peterson LB, Rothbard JB, Cummings R, and Whiteley PJ: Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the Type 1 diabetes-associated human MHC class II allele, DRB1*0401. J Clin Invest 98: 2597-2603, 1996.
51. Richter W, Mertens T, Schoel B, Muir P, Ritzkowsky A, Scherbaum WA, and Boehm B: Sequence homology of the disease-associated autoantigen glutamate decarboxylase with Coxsackie B4-2C protein and heat shock protein 60 mediates no molecular mimicry of autoantibodies: J Exp Med 180: 721-726, 1994.
52. Richter W, Northemann W, Müller M, Böhm BO: Mapping of an autoreactive epitope with glutamate decarboxylase using a diabetes-associated monoclonal antibody and an epitope cDNA library. Hybridoma 15: 103-108, 1996.
53. Daw K, Ujihara N, Atkinson M, and Powers AC: Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 156: 818-825, 1996.
54. Karounos DG, Wolinsky JS, and Thomas JW: Monoclonal antibody to rubella virus capsid protein recognizes a β-cell antigen. J Immunol 150: 3080-3085, 1993.
55. Marrack P, and Kappler J: The staphylococcal enterotoxins and their relatives. Science 248: 705-711, 1990.
56. Conrad B, Weidmann E, Tucco G, Rudert WA, Behboo R, Ricordi C, Rodriquez-Rilo H, Finegold D, and Trucco M: Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371: 351-355, 1994.
57. Conrad B, Weissmahr RN, Böni J, Arcari R, Schüpbach J, and Mach B: A human endogenous retroviral superantigen as candidate autoimmune gene in Type 1 diabetes. Cell 90: 303-313, 1997.
58. Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, Pritchard LE, Reed PW, Gough SCL, Jenkins SC, Palmer SM, Balfour KM, Rowe BR, Farrall M, Barnett AH, Bain SC, and Todd JA: A genome-wide search for human Type 1 diabetes susceptibility genes. Nature 371: 130-136, 1994.
59. Michelsen B, Wassmuth R, Ludvigsson J, Lernmark Å, Nepom GT, and Fisher L: HLA heterozygosity in insulin-dependent diabetes is most frequent at the DQ locus. Scand J Immunol 31: 405-413, 1990.
60. Thorsby E: HLA-associated disease susceptibility: which genes are primarily involved? Immunologist 3: 51-58, 1995.
61. Sanjeevi CB, Höök P, Landin-Olsson M, Kockum I, Dahlquist G, Lybrand TP, and Lernmark Å: DR4 subtypes and their molecular properties in a population base study of Swedish childhood diabetes. Tissue Antigens 47: 275-283, 1995.
62. Undlien DE, Friede T, Rammensee HG, Joner G, Dahl J-K, Sovik O, Akselsen HE, Knutsen I, Ronningen KS, and Thorsby E: HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 46: 143-149, 1997.
63. Pugliese A, Gianani R, Moromisato R, Awdeh ZL, Alper CA, Erlich HA, Jackson RA, and Eisenbarth GS: HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 44: 608-613, 1995.
64. Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE, Sundkvist G, Dahlquist G, Palmer J, and Lernmark Å: Glutamate decarboxylase-, insulin- and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest 95: 1505-1511, 1995.
65. Cucca F, Muntoni F, Lampis R, Frau F, Argiolas L, Silvetti M, Angius E, Cao A, DeVirgiliis S, and Congia M: Combinations of specific DRB1, DQA1, DQB1 haplotypes are associated with insulin-dependent diabetes mellitus in Sardinia. Hum Immunol 37: 85-94, 1993.
66. Sanjeevi CB, Lybrand TP, DeWeese C, Landin-Olsson M, Kockum I, Dahlquist G, Sundkvist G, Stenger D, and Lernmark A: Polymorphic amino acid variations in HLA-DQ are associated with systematic physical property changes and occurrence of IDDM. Diabetes 44: 125-131, 1995.
67. Todd JA, Bell JI, and McDevitt HO: HLA DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329: 599-604, 1987.
68. Khalil I, d'Auriol L, Gobet M, Morin L, Lepage V, Deschamps I, Park MS, Degos L, Galibert F, and Hors J: A combination of HLA-DQbeta Asp57-negative and HLA-DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest 85: 1315-1319, 1990.
69. Nepom BS, Nepom GT, Coleman M, and Kwok WW: Critical contribution of beta chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules. Proc Natl Acad Sci USA 93: 7202-7206, 1996.
70. Jackson DG, and Capra JD: TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined centromeric boundary of disease susceptibility. Proc Natl Acad Sci USA 90: 11079-11083, 1993.
71. Deng GY, Muir A, Maclaren NK, and She JX: Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Genet 56: 528-534, 1995.
72. Maugendre D, Alizadeh M, Gauthier A, Guilhem I, Pouillaud C, Genetet B, Allannic H, and Semana G: Genetic heterogeneity between type 1a and type 1b insulin-dependent diabetes mellitus: HLA class II and TAP gene analysis. Tissue Antigens 48: 540-548, 1996.
73. Bell GI, Aorita S, and Koran JH: A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 33: 176-183, 1984.
74. Lucassen AM, Julier C, Beressi JP, Boitard C, Froguel P, Lathrop, M., and Bell JI: Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nature Genet 4: 305-310, 1993.
75. Bennett ST, Lucassen AM, Gough SCL, Powell EE, Undlien DE, Pritchard LE, Merriman ME, Kawaguchi Y, Dronsfield MJ, Pociot F, Nerup J, Bouzekri N, Cambon-Thomasen A, Rønningen KS, Barnett AH, Bain SC, and Todd JA: Susceptibility to human Type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nature Genet 9: 284-292, 1995.
76. Bennett ST, Wilson AJ, Cucca F, Nerup J, Pociot F, McKinney PA, Barnett AH, Bain SC, and Todd JA: IDDM2-VNTR-encoded susceptibility to Type 1 diabetes: dominant protection and parental transmission of allele of the insulin gene-linked minisatellite locus. J Autoimmun 9: 415-421, 1996.
77. Vafiadis P, Bennett ST, Colle E, Grabs R, Goodyer CG, and Polychronakos C: Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leukocytes. J Autoimmun 9: 397-403, 1996.
78. Vafidias P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramashinghe S, Colle E, and Polychronakos C: Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nature Genet 15: 289-292, 1997.
79. Pugliese A, Zeller M, Fernandez JA, Zalcberg LJ, Bartlett RJ, Riocordi C, Pietropaolo M, Eienbarth SG, Bennett ST, and Patel DD: The insulin gene transcribed in the human thymus and transcription level correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for Type 1 diabetes. Nature Genet 15: 293-297, 1997.
80. Todd JA, and Farrall M: Panning for gold: genome-wide scanning for linkage in Type 1 diabetes. Hum Mol Genet 5: 1443-1448, 1996.
81. Field LL, Tobias R, and Magnus T: A locus on chromosome 15q26 (IDDM3) produces susceptibility to insulin-dependent diabetes mellitus. Nature Genet 8: 189-194, 1994.
82. Zamani M, Pociot F, Raeymaekers P, Nerup J, and Cassiman J-J: Linkage of Type 1 diabetes to 15q26 (IDDM3) in the Danish population. Hum Genet 98: 491-496, 1996.
83. Luo DF, Buzzetti R, Rotter JI, MacLaren NK, Raffel LJ, Nistico L, Giovannini C, Pozzilli P, Thomson G, and She JX: Confirmation of three susceptibility genes to insulin-dependent diabetes mellitus: IDDM4, IDDMS and IDDM8. Hum Mol Genet 5: 693-698, 1996.
84. Luo DF, Bui MM, Muir A, Maclaren NK, Thomson G, and She JX: Affected-sib-pair mapping of a novel susceptibility gene to insulin-dependent diabetes mellitus (IDDM8) on chromosome 6q25-q27. Am J Hum Genet 57: 911-919, 1995.
85. Kim PKM, Dutra AS, Chandrasekharappa SC, and Puck JM: Genomic structure and mapping of human FADD, an intracellular mediator of lymphocyte apoptosis. J Immunol 157: 5461-5466, 1996.
86. Davies JL, Cucca F, Goy JV, Atta ZAA, Merriman ME, Wilson A, Barnett AH, Bain SC, and Todd JA: Saturation multipoint linkage mapping of chromosome 6q in Type 1 diabetes. Hum Mol Genet 5: 1071-1074, 1996.
87. Merriman T, Twells R, Merriman M, Eaves I, Cox R, Cuca F, McKinney P, Shield J, Baum D, Bosi E, Pozzilli P, Nistico L, Buzzetti R, Joner G, Ronningen K, Thorsby E, Undlien D, Pociot F, Nerup J, Bain S, Barnett A, and Todd J: Evidence by allelic association-dependent methods for a Type 1 diabetes polygene (IDDM6) on chromosome 18q21. Hum Mol Genet 6: 1003-1010, 1997.
88. Hodge SE, Anderson CE, Neiswanger K, Field LL, Spence MA, Sparkes RS, Sparkes MC, Crist M, Terasaki PI, Rimoin DL, and Rotter JI: Close genetic linkage between diabetes mellitus and Kidd blood group. Lancet ii: 893-895, 1982.
89. Olives B, Merriman M, Bailly P, Bain S, Barnett A, Todd J, Cartron JP, and Merriman T: The molecular basis of the Kidd blood group polymorphism and its lack of association with Type 1 diabetes susceptibility. Hum Mol Genet 6: 1017-1020, 1997.
90. Reed P, Cucca F, Jenkins S, Merriman M, Wilson A, McKinney P, Bosi E, Joner G, Rønningen K, Thorsby E, Undlien D, Merriman TAB, Bain S, and Todd J: Evidence for a Type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11-q11. Hum Mol Genet 6: 1011-1016, 1997.
91. Wapelhorst B, Bell GI, Risch N, Spielman RS, and Concannon P: Linkage and association studies in insulin-dependent diabetes with a new dinucleotide repeat polymorphism at the GAD65 locus. Autoimmunity 21: 127-130, 1995.
92. Field LL, Tobias R, Thomson G, and Plon S: Susceptibility to insulin-dependent diabetes mellitus maps to a locus (IDDM11) on human chromosome 14q24.3-q31. Genomics 33: 1-8, 1996.
93. Copeman JB, Cucca F, Hearne CM, Cornall RJ, Reed PW, Ronningen KS, Undlien DE, Nistico L, Buzzetti R, Tosi R, Pociot F, Nerup J, Cornelis F, Barnett AH, Bain SC, and Todd JA: Linkage disequilibrium mapping of a Type 1 diabetes susceptibility gene (IDDM7) to chromosome 2q31-q33. Nature Genet 9: 80-85, 1995.
94. Nisticó L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovaninni C, Bosi E, Larrad MT, Rios MS, Chow CC, Cockram CS, Jacobs K, Mijovic C, Bain SD, Barnett AH, Vandewalle CL, Schuit F, Gorus FK, Tosi R, Pozzilli P, and Todd JA: Belgian-Diabetes Reg. The CTLA-4 gene region on chromosome 2q33 is linked to, and associated with Type 1 diabetes. Hum Mol Genet 5: 1075-1080, 1996.
95. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, and Mak TW: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270: 985-988, 1995.
96. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone J, and Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3: 541-547, 1995.
97. Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, Herwig J, Usadel KH, and Badenhoop K: CTLA4 alanine-17 confers genetic susceptibility to Graves' diease and to Type 1 diabetes mellitus. J Clin Endocrinol Metab 82: 143-146, 1997.
98. Owerbach D, Naya FJ, Tsai MJ, Allander SV, Powell DR, and Gabbay KH: Analysis of candidate genes for susceptibility to Type 1 diabetes: a case-control and family-association study of genes on chromosome 2q31-35. Diabetes 46:1069-1074, 1997.
99. Powell M, Prentice L, Asawa T, Kato R, Sawicka J, Tanaka H, Petersen V, Munkley A, Morgan S, Smith BR, and Furmaniak J: Glutamic acid decarboxylase autoantibody assay using I-125-labelled recombinant GAD(65) produced in yeast. Clin Chim Acta 256: 175-188, 1996.
100. Morahan G, Huang D, Tait BD, Colman PG, and Harrison LC: Markers on distal chromosome 2q linked to insulin-dependent diabetes mellitus. Science 272: 1811-1813, 1996.
101. Baekkeskov S, Kanatsuna T, Klareskog L, Nielsen DA, Peterson PA, Rubenstein AH, Steiner DF, and Lernmark Å: Expression of major histocompatibility antigens on pancreatic islet cells. Proc Natl Acad Sci USA 78: 6456-6460, 1981.
102. Verge CF, Gianani R, Yu L, Pietropaolo M, Smith T, Jackson RA, Soeldner JS, and Eisenbarth GS: Late progression to diabetes and evidence for chronic beta-cell autoimmunity in identical twins of patients with type I diabetes. Diabetes 44: 1176-1179, 1995.
103. Vardi P, Keller R, Dib S, Eisenbarth GS, and Soeldner JS: Log-linear correlation of CIAA with age in new onset type I diabetics. Diabetes 37: 28A, 1988.
104. Srikanta S, Ricker AT, McCulloch DK, Soeldner JS, Eisenbarth GS, and Palmer JP: Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes 35: 139-142, 1986.
105. Landin-Olsson M, Palmer JP, Lernmark A, Blom L, Sundkvist G, Nyström L, and Dahlquist G: Predictive value of islet cell and insulin autoantibodies for type 1 (insulin-dependent) diabetes mellitus in a population-based study of newly-diagnosed diabetic and matched control children. Diabetologia 35: 1068-1073, 1992.
106. Vardi P, Ziegler AG, Matthews JH, Diub S, Keller RJ, Ricker AT, Wolfsdort J, Herskowitz RD, Rabizadeh A, and Eisenbarth GS: Concentration of insulin autoantibodies at onset of type I diabetes: inverse log-linear correlation with age. Diabetes Care 9: 736-739, 1988.
107. Palmer JP, Wilkin TJ, Kurtz AB, and Bonifacio E: The third international workshop on the standardization of insulin antibody measurement. Diabetologia 33: 60-61, 1990.
108. Kuglin B, Kolb H, Greenbaum C, Maclaren NK, Lernmark A, and Palmer JP: The fourth international workshop on the standardisation of insulin autoantibody measurement. Diabetologia 33: 638-639, 1990.
109. Levy-Marchal C, Bridel M-P, Sodoyez-Goffauz F, Koch M, Richet J, Czernichow P, and Sodoyez J-C: Superiority of radiobinding assay over ELISA for detection of IAAs in newly diagnosed Type 1 diabetic children. Diabetes Care 14: 61-63, 1991.
110. Soeldner JS, Tuttleman M, Srikanta S, et al.: Insulin-dependent diabetes and autoimmunity: islet cell autoantibodies, insulin autoantibodies and beta cell failure. N Engl J Med 313: 893-894, 1985.
111. Kuglin B, Gries FA, and Kolb H: Evidence of IgG autoantibodies against human proinsulin in patients with IDDM before insulin treatment. Diabetes 37: 130-132, 1988.
112. Brusic V, Rudy G, and Harrison LC: Molecular mimicry: from hypothesis towards evidence [letter]. Immunol Today 18: 95-96, 1997.
113. Castano L, Ziegler A, Ziegler R, Shoelson S, and Eisenbarth GS: Characterization of insulin autoantibodies in relatives of patients with insulin-dependent diabetes mellitus. Diabetes 42: 1202-1209, 1993.
114. Ziegler R, Alper CA, Awdeh ZL, Castano L, Brink SJ, Soeldner JS, Jackson RA, and Eisenbarth GS: Specific association of HLA-DR4 with increased prevalence and level of insulin autoantibodies in first-degree relatives of patients with Type 1 diabetes. Diabetes 40: 709-714, 1991.
115. Pugliese A, Bugawan R, Moromisato R, Awdeh ZL, Alper CA, Jackson RA, Erlich HA, and Eisenbarth GS: Two subsets of HLA-DQA1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent diabetes. J Clin Invest 93: 2447-2452, 1994.
116. Casali P, Nakamura M, Ginsberg-Fellner F, and Notkins A: Frequency of B cells committed to the production of antibodies to insulin in newly diagnosed patients with insulin-dependent diabetes mellitus and generation of high affinity human monoclonal IgG to insulin. J Immunol 144: 3741-3747, 1990.
117. Arslanian SA, Becker DJ, Rabin B, Atchinson R, Eberhardt M, Cavender D, Dorman J, and Drash AL: Correlates of insulin antibodies in newly diagnosed children with insulin-dependent diabetes before insulin therapy. Diabetes 34: 926-930, 1985.
118. Gorus FK, Vandewalle CL, Dorchy H, Van Crombrugge P, Schuit FC, and Pipeleers DG, and the Belgian Diabetes Registry. Influence of age on the associations among insulin autoantibodies, islet cell antibodies, and HLA DQA1* 0301-DQB1*0302 and siblings of patients with type 1 (insulin-dependent) diabetes mellitus. J Clin Endocrinol Metab 78: 1172-1178, 1994.
119. Vandewalle CL, Decraene T, Schuit FC, De-Leeuw IH, Pipeleers DG, and Gorus FK: Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry. Diabetologia 36: 1155-1162, 1993.
120. Bingley PJ: Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA(+) relatives: the ICARUS data set. Diabetes 45: 1720-1728, 1996.
121. Thivolet C, Beaufrere B, Beutel H, Gebuhner L, Chatelain P, Durand A, Tourniaire J, and Francois J: Islet cell and insulin autoantibodies in subjects at high risk for the development of type 1 (insulin-dependent) diabetes mellitus: the Lyon family study. Diabetologia 31: 741-746, 1988.
122. McCulloch DK, Klaff LJ, Kahn SE, Schoenfeld SL, Greenbaum CJ, Mauset RS, Benson EA, Nepom GT, Shewey L, and Palmer JP: Nonprogression of subclinical β-cell dysfunction among first degree relatives of IDDM patients: 5-yr follow-up of the Seattle family study. Diabetes 39: 549-556, 1990.
123. Bärmeier H, McCulloch DK, Neifing JL, Warnock G, Rajotte RV, Palmer JP, and Lernmark Å: Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies. Diabetologia 34: 727-733, 1991.
124. Sochett E, and Daneman D: Relationship of insulin autoantibodies to presentation and early course of IDDM in children. Diabetes Care 12: 517-523, 1989.
125. Levy-Marchal C, Tichet J, Fajardy I, Gu XF, Dubois F, and Czernichow P: Islet cell antibodies in normal French school-children. Diabetologia 35: 577-582, 1992.
126. Rowe RE, Leech NJ, Nepom GT, and McCulloch DK: High genetic risk for IDDM in the Pacific Northwest. First report from the Washington State Diabetes Prediction Study. Diabetes 43: 87-94, 1994.
127. Daniel D, Gill RG, Schloot N, and Wegmann D: Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 25: 1056-1062, 1995.
128. Wegmann DR, Gill RG, and Daniel D: The role of insulin-specific T cells in IDDM in NOD mice. In 13th Immunology and Diabetes Workshop, Montvillargenne, France, 1994, p. 12.
129. Böhmer K, Keilacker H, Kuglin B, Hübinger A, Bertrams J, Gries FA, and Kolb H: Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies. Diabetologia 34: 830-834, 1991.
130. Rudy G, Stone N, Harrison LC, Colman PG, McNair P, Brusic V, French MB, Honeyman MC, Tait B, and Lew AM: Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol Med 1: 625-633, 1995.
131. Bu D-F, Erlander MG, Hitz BC, Tillakaratne NJK, Kaufman DL, Wanger-McPherson CB, Evans GA, and Tobin AJ: Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci USA 89: 2115-2119, 1992.
132. Erdö SL, and Wolff JR: Gamma-aminobutyric acid outside the mammalian brain. J Neurochem 54: 363-372, 1990.
133. Martin DL: Short-term control of GABA synthesis in brain. Prog Biophys Mol Biol 60: 17-28, 1993.
134. Okada Y, Taniguchi H, and Shimada C: High concentration of GABA and high glutamate decarboxylase activity in rat pancreatic islets and human insulinoma. Science 194: 620-622, 1976.
135. Okada Y: Localization and function of GABA in the pancreatic islets. In GABAergic Mechanisms in the Mammalian Periphery, Bowery NG, and Erdö SL, Ed. Raven Press, New York, 1986, pp. 223-240.
136. Persson Å, Pelto-Huikko M, Metsis M, Söder O, Brené S, Skog S, Hökfelt T, and Ritzén M: Expression of the neurotransmitter-synthesizing enzyme glutamic acid decarboxylase in male germ cells. Mol Cell Biol 10: 4701-4711, 1990.
137. Hagopian WA, Michelsen B, Karlsen AE, Larsen F, Moody A, Grubin CE, Rowe R, Petersen J, McEvoy R, and Lernmark Å: Autoantibodies in IDDM primarily recognize the 65,000-Mr rather than the 67,000-Mr isoform of glutamic acid decarboxylase. Diabetes 42: 631-636, 1993.
138. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GSP, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, and Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72, 1993.
139. Tisch R, Yang X-D, Singer SM, Liblau RS, Fugger L, and McDevitt HO: Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75, 1993.
140. Ma SW, Zhao DL, Yin ZQ, Mukherjee R, Singh B, Qin HY, Stiller CR, and Jevnikar AM: Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med 3: 793-796, 1997.
141. Martin DL, Martin SB, Wu S, and Espina N: Regulatory properties of brain glutamate decarboxylase: the apoenzyme of GAD is present principally as one of two molecular forms of GAD in brain. J Neurosci 11: 2725-2731, 1991.
142. Martin DL, and Rimvall K: The regulation of GABA synthesis in the brain. J Neurochem 60: 395-407, 1993.
143. Sheikh S, and Martin DL: Heteromers of glutamate decarboxylase isoforms occur in cerebellum. J Neurochem 66:2082-2090,1996.
144. 67 protein is highly sensitive to small increases in intraneuronal gamma-aminobutyric acid levels. J Neurochem 62: 1375-1381, 1994.
145. Baekkeskov S, Warnock G, Christie M, Rajotte RV, Larsen PM, and Fey S: Revelation of specificity of 64K autoantibodies in IDDM serums by high-resolution 2-D gel electrophoresis. Diabetes 38: 1133-1141, 1990.
146. Christgau S, Schierbeck H, Aanstoot H-J, Aagaard L, Begley K, Kofod H, Hejnaes K, and Baekkeskov S: Pancreatic β cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble. J Biol Chem 286: 21257-21264, 1991.
147. Karlsen AE, Hagopian WA, Petersen JS, Boel E, Dyrberg T, Grubin CE, Michelsen BK, Madsen OD, and Lernmark Å: Recombinant glutamic acid decarboxylase representing a single isoform expressed in human islets detects IDDM associated 64K autoantibodies. Diabetes 41: 1355-1359, 1992.
148. Dirkx R Jr, Thomas A, Linsong L, Lernmark Å, Sherwin RS, De Camilli P, and Solimena M: Targeting of the 67-kDa isoform of glutamic acid decarboxylase to intracellular organelles is mediated by its interaction with the NH2-terminal region of the 65-kDa isoform of glutamic acid decarboxylase. J Biol Chem 270: 2241-2246, 1995.
149. Ling Z, Malaisse-Lagae F, Malaisse WJ, and Pipeleers D: Reduced glutamate decarboxylase activity in rat islet beta cells which survive streptozotocin-induced cytotoxicity. FEBS Lett 324: 262-264, 1993.
150. Smismans A, Ling Z, and Pipeleers D: Damaged rat beta cells discharge glutamate decarboxylase in the extracellular medium. Biochem Biophys Res Commun 228: 293-297, 1996.
151. Michalik M, Nelson J, and Erecinska M: GABA production in rat islets of Langerhans. Diabetes 42: 1506-1513, 1993.
152. Vincent ST, Hökfelt T, Wu J-Y, Eide RP, Morgan LM, and Kimmel JR: Immunohistochemical studies of the GABA system in the pancreas. Neuroendocrinology 36: 197-204, 1983.
153. A receptors. In GABAergic Synaptic Transmission, Biggio G, Concas A, and Costa E, Eds. Raven Press, New York, 1992, pp. 55-66.
154. Gilon P, Bertrand G, Loubatieres-Mariani MM, Remacle C, and Henquin JC: The influence of γ-aminobutyric acid on hormone release by the mouse and rat endocrine pancreas. Endocrinology 129: 2521-2529, 1991.
155. Rorsman P, Berggren PO, Bokvist K, Ericson H, Möhler H, Östensson CG, and Smith PA: Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. Nature 341: 233-236, 1989.
156. Lernmark A: Glutamic acid decarboxylase: gene to antigen to disease. J Intern Med 240: 259-277, 1996.
157. Hagopian WA, Karlsen AE, Petersen JS, Teague J, Gervassi A, Jiang J, Fujimoto W, and Lernmark Å: Regulation of glutamic acid decarboxylase diabetes autoantigen expression in highly purified isolated islets from Macaca nemestrina. Endocrinology 132: 2674-2681, 1993.
158. Velloso LA, Kämpe O, Hallberg A, Christmanson L, Betsholtz C, and Karlsson FA: Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in Type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest 91: 2084-2090, 1993.
159. 3H recombinant human ligands. J Immunol Meth 186: 89-99, 1995.
160. Vandewalle CL, Falorni A, Svanholm S, Lernmark A, Pipeleers DG, and Gorus FK: High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J Clin Endocrinol Metab 80: 846-851, 1995.
161. Seissler J, Amann J, Mauch L, Haubruck H, Wolfahrt S, Bieg S, Richter W, Holl R, Heinze E, Northemann W, and Scherbaum WA: Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 92: 1394-1399, 1993.
162. DeAizpurua HJ, Harrison LC, and Cram DS: An ELISA for antibodies to recombinant glutamic acid decarboxylase in IDDM. Diabetes 41: 1182-1187, 1992.
163. Schmidli RS, DeAizpurua HJ, Harrison LC, and Colman PG: Antibodies to glutamic acid decarboxylase in at-risk and clinical insulin-dependent diabetic subjects: relationship to age, sex and islet cell antibody status, and temporal profile. J Autoimmun 7: 55-66, 1994.
164. Genovese S, Bingley PJ, Bonifacio E, Christie MR, Shattock M, Bonfanti R, Foxon R, Gale EAM, and Bottazzo GF: Combined analysis of IDDM-related autoantibodies in healthy school children. Lancet 344: 756, 1994.
165. Rowley MJ, Mackay JR, Chen Q-Y, Knowles WJ, and Zimmet PZ: Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 41: 548-551, 1992.
166. Gianani R, Rabin DU, Verge CF, Yu L, Babu SR, Pietropaolo M, and Eisenbarth GE: ICA512 autoantibody radioassay. Diabetes 44: 1340-1344, 1995.
167. Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Bognetti E, Bottazzo GF, Gale EAM, and Bosi E: Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38: 816-822, 1995.
168. Falorni A, Nikosjkov A, Laureti S, Grenbäck, Hulting A-L, Casucci G, Santeusanio F, Brunetti P, Luthman H, and Lernmark Å: High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 80: 2752-2755, 1995.
169. Hagopian W, Kockum I, Sundkvist G, Landin-Olsson M, Sanjeevi C, Östman J, Blohme G, Nyström L, Wibell L, Lithner F, Schersten B, Lernmark Å. (1995) Antibodies to GAD remain highly prevalent in adult-onset autoimmune diabetes: a comparison of population-based studies in 15-34 and 0-15 year old Swedish diabetic patients. Diabetes 44 (suppl 1) 240A, 1995.
170. Yu L, Chase HP, Falorni A, Rewers M, Lernmark Å, and Eisenbarth GS: Sexual dimorphism in transmission to offspring of expression of islet autoantibodies. Diabetologia 38: 1353-1357, 1995.
171. Ivarsson SA, Ackefors M, Carlsson A, Ekberg G, Falorni A, Kockum I, Landin-Olsson M, Lernmark Å, Lindberg B, Sundkvist G, and Svanberg L: Glutamate decarboxylase antibodies in non-diabetic pregnancies precedes insulin-dependent diabetes in the mother but not necessarily in the offspring. Autoimmunity 26: 261-269, 1997.
172. Norris JM, Beaty B, Klingensmith G, Yu L, Hoffman M, Chase HP, Erlich HA, Hamman RF, Eisenbarth GS, and Rewers M: Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY). JAMA 276: 609-614, 1996.
173. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, Norris J, and Eisenbarth GS: Anti islet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 81: 4264-4267, 1996.
174. Kawasaki E, Takino H, Yano M, Uotani S, Matsumoto K, Takao Y, Yamaguchi Y, Akazawa S, and Nagataki S: Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 43: 80-86, 1994.
175. Sundkvist G, Velloso LA, Kämpe O, Rabinowe SL, Ivarsson SA, Lilja B, and Karlsson FA: Glutamic acid decarboxylase antibodies, autonomic nerve antibodies and autonomic neuropathy in diabetic patients. Diabetologia 37: 293-299, 1994.
176. Tuomi T, Björses P, Falorni A, Partanen J, Perheentupa J, Lernmark Å, and Miettinen A: Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 81: 1488-1494, 1996.
177. Björk E, Velloso LA, Kämpe O, and Karlsson FA: GAD autoantibodies in IDDM, Stiff-Man Syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes 43: 161-165, 1994.
178. Hallengren B, Falorni A, Landin-Olsson M, Lernmark Å, Papadopoulos KI, and Sundkvist G: Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients: at diagnosis and following treatment. J Intern Med 239: 63-68, 1996.
179. Tsuruoka A, Matsuba I, Toyota T, Isshiki G, Nagataki S, and Ikeda Y: Antibodies to GAD in Japanese diabetic patients: a multicenter study. Diabetes Res Clin Pract 28: 191-199, 1995.
180. Powell M, Prentice L, Asawa T, Kato R, Sawicka J, Tanaka H, Petersen V, Munkley A, Morgan S, Rees S-B, and Furmaniak J: Glutamic acid decarboxylase autoantibody assay using 1251-labelled recombinant GAD65 produced in yeast. Clin Chim Acta 256: 175-188, 1996.
181. Daw K, and Powers AC: Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target difference epitopes. Diabetes 44: 216-220, 1995.
182. Falorni A, Ackefors M, Carlberg C, Daniels T, Persson B, Robertson J, and Lernmark Å: Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies epitopes in childhood IDDM. Diabetologia 39: 1091-1098, 1996.
183. Syren K, Lindsay L, Stoehrer B, Jury K, Luhder F, Baekkeskov S, and Richter W: Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. J Immunol 157: 5208-5214, 1996.
184. Butler MH, Solimena M, Dirkx J, R., Hayday A, and De Camilli P: Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in Stiff-Man syndrome. J Exp Med 178: 2097-2106, 1993.
185. Kim J, Namchuck M, Bugavvan T, Fu Q, Jaffe M, Shi Y, Aanstoot H-J, Turck CW, Erlich H, Lennon V, and Baekkeskov S: Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish Stiff-Man Syndrome from insulin-dependent diabetes mellitus. J Exp Med 180: 595-606, 1994.
186. Li L, Hagopian WA, Brashear HR, Daniels T, and Lernmark Å: Identification of autoantibody epitopes of glutamic acid decarboxylase in Stiff-Man Syndrome patients. J Immunol 152: 930-934, 1994.
187. Richter W, Endl J, Eiermann TH, Brandt M, Kientsch-Engel R, Thivolet C, Jungfer H, and Scherbaum WA: Human monoclonal islet cell antibodies from a patient with insulin-dependent diabetes mellitus reveal glutamate decarboxylase as the target antigen. Proc Natl Acad Sci USA 89: 846-847, 1992.
188. Richter W, Jury KM, Loeffler D, Manfras BJ, Eiermann TH, and Boehm BO: Immunoglobulin variable gene analysis of human autoantibodies reveals antigen-driven immune response to glutamate decarboxylase in Type 1 diabetes mellitus. Eur J Immunol 25: 1703-1712, 1995.
189. Madec AM, Rousset F, Ho S, Robert F, Thivolet C, Orgiazzi J, and Lebecque S: Four IgG anti-islet human monoclonal antibodies isolated from a Type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated. J Immunol 156: 3541-3549, 1996.
190. Atkinson MA, Kaufman DL, Campbell L, Gibbs KA, Shah SC, Bu D-F, Erlander MG, Tobin AJ, and Maclaren NK: Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 339: 458-459, 1992.
191. Harrison LC, Honeyman MC, Deaizpurua HJ, Schmidli RS, Colman PC, Tait BD, and Cram DS: Inverse regulation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341: 1365-1369, 1993.
192. Worsaae A, Hejnaes K, Moody A, Ludvigsson J, Pociot F, Lorenzen T, and Dyrberg T: T cell proliferative responses to glutamic acid decarboxylase-65 in IDDM are negatively associated with HLA-DR3/4. J Autoimmunity 22: 183-189, 1995.
193. Honeyman MC, Cram DS, and Harrison LC: Glutamic acid decarboxylase 67-reactive T cells: a marker of insulin-dependent diabetes. J Exp Med 177: 535-540, 1993.
194. Honeyman MC, Stone N, de Aizpurua H, Rowley MJ, and Harrison LC: High T cell responses to the glutamic acid decarboxylase (GAD) isoform 67 reflect a hyperimmune state that precedes the onset of insulin-dependent diabetes. J Autoimmun 10: 165-173, 1997.
195. Lohmann T, Leslie RDG, Hawa M, Geysen M, Rodda S, and Londei M: Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus. Lancet 343: 1607-1608, 1994.
196. Kwok WW, Nepom GT, and Raymond FC: HLA-DQ polymorphisms are highly selective for peptide binding interactions. J Immunol 155: 2468-2476, 1995.
197. Kwok WW, Domeier ML, Raymond FC, Byers P, and Nepom GT: Allele-specific motifs characterize HLA-DQ interactions with a diabetes-associated peptide derived from glutamic acid decarboxylase. J Immunol 156: 2171-2177, 1996.
198. Patel SD, Cope AP, Congia M, Chen TT, Kim E, Fugger L, Wherrett D, and Sonderstrup M-G: Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha1*0101,beta1*0401) transgenic mice. Proc Natl Acad Sci USA 94: 8082-8087, 1997.
199. Petersen JS, Karlsen AE, Markholst H, Worsaae A, Dyrberg T, and Michelsen B: Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes 43: 1478-1484, 1994.
200. Godkin A, Friede T, Davenport M, Stefanovic S, Willis A, Jewell D, and Hill A, and Ramensee H-G: Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Internat Immunol 9: 905-911, 1997.
201. Panina-Bordignon P, Lang R, van Endert PM, Benazzi E, Felix AM, Pastore RM, Spinas GA, and Sinigaglia F: Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 181: 1923-1927, 1995.
202. Christie MR, Vohra G, Champagne P, Daneman D, and Delovitch TL: Distinct antibody specificities to a 64-kD islet cell antigen in Type 1 diabetes as revealed by trypsin treatment. J Exp Med 172: 789-794, 1990.
203. Christie MR, Brown TJ, and Cassidy D: Binding of antibodies in sera from type 1 (insulin-dependent) diabetic patients to glutamate decarboxylase from rat tissues: evidence for antigenic and non-antigenic forms of the enzyme. Diabetologia 35: 380-384, 1992.
204. Christie MR, Hollands JA, Brown TJ, Michelsen BM, and Delovitch TL: Detection of pancreatic islet 64,000 Mr autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylase. J Clin Invest 92: 240-248, 1993.
205. Rabin DU, Pleasic SM, Palmer-Crocker R, and Shapiro JA: Cloning and expression of IDDM-specific human autoantigens. Diabetes 41: 183-186, 1992.
206. Lan MS, Modi WS, Xie H, and Notkins AL: Assignment of the IA-2 gene encoding an autoantigen in IDDM to chromosome 2q35 [letter]. Diabetologia 39: 1001-1002, 1996.
207. Solimena M, Dirkx R, Jr., Hermel JM, Pleasic WS, Shapiro JA, Caron L, and Rabin DU: ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. Embo J 15: 2102-2114, 1996.
208. Stone RL, and Dixon JE: Protein-tyrosine phosphatases. J Biol Chem 269: 31323-31326, 1994.
209. Xie H, Zhang BW, Matsumoto Y, Li Q, Notkins AL, and Lan MS: Autoantibodies to IA-2 and IA-2 beta in insulin-dependent diabetes mellitus recognize conformational epitopes: location of the 37- and 40-kDa fragments determined. J Immunol 159: 3662-3667, 1997.
210. Kawasaki E, Yu L, Gianani R, Verge CF, Babu S, Bonifacio E, and Eisenbarth GS: Evaluation of islet cell antigen (ICA) 512/IA-2 autoantibody radioassays using overlapping ICA512/IA-2 constructs. J Clin Endocrinol Metab 82: 375-380, 1997.
211. Christie MR, Genovese S, Cassidy D, Bosi E, Brown TJ, Lai M, Bonifacio E, and Bottazzo GF: Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 43: 1254-1259, 1994.
212. Bonifacio E, Lampasona V, Genovese S, Ferrari M, and Bosi E: Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 155: 5419-5426, 1995.
213. Gorus FK, Goubert P, Semakula C, et al: IA-2-autoantibodies complement GAD(65)-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. Diabetologia 40: 95-99, 1997.
214. Lampasona V, Bearzatto M, Genovese S, Bosi E, Ferrari M, and Bonifacio E: Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 157: 2707-2711, 1996.
215. Sanjeevi CB, Falorni A, Kockum I, Hagopian WA, and Lernmark Å: HLA and glutamic acid decarboxylase in human insulin-dependent diabetes mellitus. Diabetic Med 13: 209-217, 1996.
216. LaGasse J, Jelinek L, Sexson S, LoftonDay C, Breininger J, Sheppard P, Kindsvogel W, and Hagopian WA: An islet-cell protein tyrosine phosphatase is a likely precursor to the 37-kDa autoantigen in Type 1 diabetes: human and macaque sequences, tissue distribution, unique and shared epitopes, and predictive autoantibodies. Mol Med 3: 163-173, 1997.
217. Martin JM, Trink B, Daneman D, Dosch H-M, and Robinson B: Milk proteins in the etiology of insulin-dependent diabetes mellitus (IDDM). Ann Med 23: 447-452, 1991.
218. Pietropaolo M, Castano L, Babu S, Buelow R, Kuo Y-LS, Martin S, Martin A, Powers AC, Prochazka M, Naggert J, Leiter EH, and Eisenbarth GS: Islet cell autoantigen 69KDa (ICA69): molecular cloning and characterization of a novel diabetes-associated autoantigen. J Clin Invest 92: 359-371, 1993.
219. Karjalainen J, Martin JM, Knip M, Ilonen J, Robinson BH, Savilathi E, Åkerblom H, and Dosch H-M: A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 327: 302-307, 1992.
220. Karges W, Pietropaolo M, Ackerley CA, and Dosch HM: Gene expression of islet cell antigen p69 in human, mouse and rat. Diabetes 45: 513-521, 1996.
221. Mally MI, Cirulli V, Otonkoski T, Soto G, and Hayek A: Ontogeny and tissue distribution of human GAD expression. Diabetes 45: 496-501, 1996.
222. Martin S, Kardorf J, Schulte B, Lampeter EF, Gries FA, Melchers I, Wagner R, Bertrams J, Roep BO, Pfützner A, Pietropaolo M, and Kolb H: Autoantibodies to the islet antigen ICA 69 occur in IDDM and in rheumatoid arthritis. Diabetologia 38: 351-355, 1995.
223. Roep BO, Duinkerken G, Schreuder GM, Kolb H, de Vries RR, and Martin S: HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Eur J Immunol 26: 1285-1289, 1996.
224. Aanstot HJ, Kang SM, Kim J, Lindsay LA, Roll U, Knip M, Atkinson M, Mose-Larsen P, Fey S, Ludvigsson J, Landin-Olsson M, Bruining J, Maclaren N, Akerblom HK, and Baekkeskov S: Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD(65) and IA2 marks the early phases of autoimmune response in Type 1 diabetes. J Clin Invest 97: 2772-2783, 1996.
225. Honeyman MC, Cram DS, and Harrison LC: Transcription factor jun-B is target of auto-reactive T-cells in IDDM. Diabetes 42: 626-630, 1993.
226. Castano L, Russo E, Zhou L, Lipes M, and Eisenbarth G: Identification and cloning of a granule autoantigen (carboxypeptidase-H) associated with Type 1 diabetes. J Clin Endocrinol Metab 73: 1197-1201, 1991.
227. Elias D, Reshef T, Birk OS, van der Zee R, and Cohen IR: Vaccination against autoimmune mouse diabetes with a T-cell epitope of human 65-kDa heat shock protein. Proc Natl Acad Sci USA 88: 3088-3091, 1991.
228. Jones DB, Hunter NR, and Duff GW: Heatshock protein 65 as a β cell antigen of insulin-dependent diabetes. Lancet 336: 583-598, 1990.
229. Ozawa Y, Kasuga A, Nomaguchi H, Maruyama T, Kasatani T, Shimada A, Takei I, Miyazaki J, and Saruta T: Detection of autoantibodies to the pancreatic islet heat shock protein 60 in insulin-dependent diabetes mellitus. J Autoimmun 9: 517-524, 1996.
230. Velloso LA, Winqvist O, Gustafsson J, Kämpe O, and Karlsson FA: Autoantibodies against a novel 51 kDa islet antigen and glutamate decarboxylase isoforms in autoimmune polyendocrine syndrome type I. Diabetologia 37: 61-69, 1994.
231. Rorsman F, Husebye ES, Winqvist O, Björk E, Karlsson FA, and Kämpe O: Aromatic L-amino acid decarboxylase, a pyridoxalphosphate-dependent enzyme, is a beta cell autoantigen. Proc Natl Acad Sci USA 92: 8626-8629, 1995.
232. Husebye ES, Gebre-Medhin G, Tuomi T, Perheentupa J, Landin-Olsson M, Gustafsson J, Rorsman F, and Kämpe O: Autoantibodies against aromatic 1-amino acid decarboxylase in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 82: 147-150, 1997.
233. Huang SW, Hallquist Haedt L, Rich S, and Barbosa J: Prevalence of antibodies to nucleic acids in insulin-dependent diabetes and their relatives. Diabetes 30: 873-874, 1981.
234. Chang YH, Hwang J, Shang HF, and Tsai ST: Characterization of human topoisomerase II as an autoantigen recognized by patients with IDDM. Diabetes 45: 408-414, 1996.
235. Nayak RC, Omar MAK, Rabizadeh A, Srikanta S, and Eisenbarth GS: "Cytoplasmic" islet cell antibodies: evidence that the target antigen is a sialoglycoconjugate. Diabetes 34: 617-619, 1985.
236. Colman PG, Nayak RC, Campbell IL, and Eisenbarth GS: Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes 37: 645-652, 1988.
237. Dotta F, Previti M, Lenti L, Dionisi S, Casetta B, D'Erme M, Eisenbarth GS, and Di Mario U: GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. Diabetologia 38: 1117-1121, 1995.
238. Arden SD, Roep BO, Neophytou PI, Usac EF, Duinkerken G, de Vries RRP, and Hutton JC: Imogen 38: a novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed Type 1 diabetic patient. J Clin Invest 97: 551-561, 1996.
239. Van de Water J, Cooper A, Surh CD, Coppel R, Danner D, Ansari A, Dickson R, and Gershwin ME: Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 320: 1377-1380, 1989.
240. Roll U, Christie MR, Fuchtenbusch M, Payton MA, Hawkes CJ, and Ziegler AG: Perinatal autoimmunity in offspring of diabetic parents. The German Multicenter BABY-DIAB study: detection of humoral immune responses to islet antigens in early childhood. Diabetes 45: 967-973, 1996.
241. Nyström L, Dahlquist G, Östman J, Wall S, Arnqvist H, Blohmé G, Lithner F, Littorin B, Schersten B, and Wibell L: Risk of developing insulin-dependent diabetes mellitus (IDDM) before 35 years of age: indications of climatological determinants for age at onset. Int J Epidemiol 21: 352-358, 1992.
242. Lorenzen T, Pociot E, Hougaard P, and Nerup J: Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia 37: 321-327, 1994.
243. Mason DR, Scott RS, and Darlow BA: Epidemiology of insulin-dependent diabetes mellitus in Canterbury, New Zealand. Diab Res Clin Practice 3: 21-29, 1987.
244. Ramiya VK, Lan MS, Wasserfall CH, Notkins AL, and Maclaren NK: Immunization therapies in the prevention of diabetes. J Autoimmun 10: 287-292, 1997.
245. Tian J, Atkinson MA, Clare S-M, Herschenfeld A, Forsthuber T, Lehmann PV, and Kaufman DL: Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183: 1561-1567, 1996.
246. Tian J, Clare S-M, Herschenfeld A, Middleton B, Newman D, Mueller R, Arita S, Evans C, Atkinson MA, Mullen Y, Sarvetnick N, Tobin AJ, Lehmann PV, and Kaufman DL: Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2: 1348-1353, 1996.
247. Herskowitz RD, Jackson RA, Soeldner JS, and Eisenbarth GS: Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. J Autoimmun 2: 733-737, 1989.
248. Luo DF, Maclaren NK, Huang HS, Muir A, and She JX: Intrafamilial and case-control association analysis of D2S152 in insulin-dependent diabetes. Autoimmunity 21: 143-147, 1995.